Since PD-L1 on immune cells is associated with immunotherapy treatment response in advanced urothelial carcinoma patients, more investigation is required on clinical uses for the biomarker and drug development involving the PD-1/PD-L1 pathway inhibitors involving pembrolizumab. Here, CD274 is linked to urothelial carcinoma.